Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Shivani Kumaresan

XpresSpa Extends Partnership With CDC For Biosurveillance At US Airports

  • XpresSpa Group Inc (NASDAQ:XSPA) has extended its initial $2 million airport-based biosurveillance program with the Centers for Disease Control and Prevention (CDC) through its subsidiary XpresCheck. The extension brings the total contract to $5.6 million.
  • The COVID-19 biosurveillance program, first launched in September 2021, provided testing for travelers arriving from India at three key U.S. airports, including John F. Kennedy International Airport, Newark-Liberty International Airport, and San Francisco International Airport. 
  • With the recent expansion, the program now tests passengers entering the U.S. from seven African countries, including passengers making connections through the U.K., France, Germany, and Brazil.
  • The expansion includes the addition of Hartsfield-Jackson Atlanta International Airport, bringing the number of testing sites to four.
  • Price Action: XSPA shares traded higher by 4.10% at $1.40 on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.